Polycythemia: Lecture Slides Pratap Sagar Tiwari, MD

Polycythemia
Lecture slides
Pratap Sagar Tiwari, MD
Definition
 It is a disease state in which the proportion of blood

volume that is occupied by red blood cells increases.
 An increase in the no of red blood cells =absolute
polycythemia
 Due to decrease in the volume of plasma =relative
polycythemia
Definition.. continue
 Hematocrit — Polycythemia in the adult patient is

suspected when the HCT is >48 or >52 % in F and M,
respectively.
 (The hematocrit (HCT) is expressed as the percent of a
blood sample occupied by intact RBCs. )
 Hemoglobin concentration — when the HGB is >16.5 or
>18.5 g/dL in F and M, respectively.
 (The hb concentration (HGB) is its content in grams per
100 mL of whole blood. )
Polycythemia
Absolute Relative
Increase rbc Decrease bld volume
Primary Polycythemia Secondary overtransfusion
Myeloproliferative disorder Dec O2, altitude, Ca

Polycythemia Vera
Relative polycythemia
 It is an apparent rise of the erythrocyte level in the

blood.
 The underlying cause is reduced blood plasma.
 Relative polycythemia is often caused by loss of body
fluids, such as through burns, dehydration and stress.
 A specific type of relative polycythemia is Gaisböck
syndrome: mild obesity, diastolic htn, ↓ in plasma vol
with relative ↑ in RBC
Absolute polycythemia
 Overproduction of RBC may be due to a primary

process in the bone marrow= myeloproliferative
syndrome
 May be a reaction to chronically low oxygen levels.
 Overtransfusion
SP:Erythropoietin secreting tumors
 Renal-cell carcinoma
 liver tumors
 von Hippel-Lindau disease
 Uterine fibroids
 Hemangioblastoma
SP:Hypoxemia secondary to:
 Chronic pulmonary disease

 Right-to-left cardiac shunts
 Sleep apnea
 Massive obesity (Pickwickian syndrome)
 High altitude
 Chronic carbon monoxide poisoning (including heavy
smoking)
PP: Polycythemia Vera
 Polycythemia vera is one of the chronic

myeloproliferative disorders (neoplasms), collectively
characterized by clonal proliferation of myeloid cells.
 The most prominent feature of this disease is an
elevated absolute RBC mass because of uncontrolled
red blood cell production.
 This is accompanied by ↑ WBC and platelet production
as well.
Pathophysiology
 There is mutation on the Janus kinase-2 gene (JAK2)

 JAK2 is directly involved in the intracellular signaling
of progenitor cells in bone marrow.
 The peak incidence of PV is age 50-70 years.
Presentation
 Symptoms of PV are often insidious in onset, and they are

often related to blood hyperviscosity.
 Symptoms are related to
1. hyperviscosity
2. sludging of blood flow
3. thromboses
 which lead to poor oxygen delivery and symptoms that
include headache, dizziness, vertigo, tinnitus, visual
disturbances, angina pectoris, or intermittent claudications.
Presentation……….continue
 Bleeding complications (1%) include epistaxis, gum

bleeding, ecchymoses, and gastrointestinal (GI)
bleeding.
 Thrombotic complications (1%) include venous
thrombosis or thromboembolism and an ↑prevalence
of stroke and other arterial thromboses.
Presentation……….continue
 Abdominal pain due to PUD is present because PV is

associated with ↑ histamine levels and gastric acidity.
 Splenomegaly, when present, can cause early satiety
because of gastric filling being impaired by the
enlarged spleen .
 Pruritus(40%) results from ↑ histamine levels released
from ↑ basophils and mast cells.
Physical
 Plethoric face
 Splenomegaly –75%
 Hepatomegaly –30%
Investigation
 Polymerase chain reaction :JAK2 mutation

 Serum Epo assay: are often below the lower limit of
normal .
 Leukocyte alkaline phosphatase distinguises PV from

CML.
Treatment
 Phlebotomy or bloodletting.
 (Reduce the hematocrit to the range of <45%.)
 Anagrelide is a inhibits megakaryocyte maturation, thereby decreasing
platelet counts.
 JAK1/JAK2 inhibitor : ruxolitinib
 Hydroxyurea & Interferon alfa
 PROGNOSIS — The median survival of untreated symptomatic

patients with PV was initially estimated at 6 to 18 months from the time
of diagnosis, whereas current survival of treated patients is 10 years or
more.
End of slides

Polycythemia: Lecture Slides Pratap Sagar Tiwari, MD

Uploaded by

Copyright:

Available Formats

Polycythemia: Lecture Slides Pratap Sagar Tiwari, MD

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Polycythemia: Lecture Slides Pratap Sagar Tiwari, MD

Uploaded by

Copyright:

Available Formats

Polycythemia

 It is a disease state in which the proportion of blood

 Hematocrit — Polycythemia in the adult patient is

Increase rbc Decrease bld volume

Primary Polycythemia Secondary overtransfusion

Myeloproliferative disorder Dec O2, altitude, Ca

 It is an apparent rise of the erythrocyte level in the

 Overproduction of RBC may be due to a primary

 Chronic pulmonary disease

 Polycythemia vera is one of the chronic

 There is mutation on the Janus kinase-2 gene (JAK2)

 Symptoms of PV are often insidious in onset, and they are

 Bleeding complications (1%) include epistaxis, gum

 Abdominal pain due to PUD is present because PV is

 Polymerase chain reaction :JAK2 mutation

 Leukocyte alkaline phosphatase distinguises PV from

 PROGNOSIS — The median survival of untreated symptomatic

You might also like